Urgo Medical North America (formerly SteadMed Medical) Obtains Federal Supply Schedule Contract for VASHE® Product Line
by SteadMed Medical
Fort Worth, TX – October 1, 2018 — Urgo Medical North America (formerly SteadMed Medical), announced a new Federal Supply Schedule contract for its VASHE product line. The contract provides the Military Health System broad access to VASHE®, Vashe provides skin-friendly wound care with the highest concentration of pure hypochlorous acid* available on the market today. Vashe® Wound Solution is intended for cleansing, irrigating, moistening, debriding and removal of foreign material including microorganisms and debris from exudating and/or dirty wounds, acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second-degree burns, grafted and donor sites; and exit sites. Vashe® Wound Solution passes the USP<51> Antimicrobial Effectiveness Test, and demonstrates rapid effective activity in solution against a broad spectrum of gram-positive, gram-negative, and yeast species with the following in vitro time-kill results.
The Military Health System encompasses the U.S. Department of Defense’s institutions providing health care to active duty and retired U.S. Military personnel and their dependents. This system provides healthcare coverage to 10.2 million lives. Urgo Medical North America, is partnering exclusively with Alliant Healthcare, a verified Service-Disabled, and Veteran-Owned Small Business (SDVOSB). As an SDVOSB, Alliant is a priority provider of medical products and services to the Federal government with an extensive sales history with every VA and DoD hospital worldwide. Alliant provides customer support for the Urgo Medical North America technologies delivered to the Military Health System.
VASHE is available under codes FSS #V797D-50441 and DAPA #SP0200-05-H-0090.
“We are pleased that we can now offer contract access of our market leading technology for the nation’s Veterans, Active Duty Military patients and the clinicians delivering care to them,” said Michael Steadman, Chief Executive Officer of Urgo Medical North America. Recognition of the clinical benefits and superiority that our proprietary technology offers to patients continues to deepen among providers, now including broad accessibility to our nations Veterans through this contract.”
SteadMed Medical provides medical devices and products to hospitals, nursing homes and home health agencies – and the patients they treat – with a focus on acute, chronic, and surgical wounds, and additionally skin moisturization. Our extensive portfolio of products establishes proven protocols for the care and management of wounds, skin, and skin breakdown. By listening to clinicians’ concerns, SteadMed has been able to provide the highest-quality and most innovative products available, while keeping costs competitive. Its dedicated field representatives and customer service department, as well as clinical personnel on staff, are committed to supporting the needs of the clinician. These professionals enable SteadMed to bring comprehensive solutions to those with wound and skin care complications.
For more information, please visit https://www.steadmed.com
About URGO GROUP
French Family-owned URGO Group is an international leading company and world expert in advanced wound care and selfcare. With its two divisions Urgo Medical and Urgo Consumer Healthcare, URGO Group is engaged on day to day basis with patients, healthcare professionals and the general public. The Group develops innovative wound dressings that have proven their medical superiority through clinical studies, to address an increased need worldwide for the care of chronic wounds. It gives access to responsible healthcare solutions in the areas of first aid, nutritional supplements, sexual well-being, cold and allergies. The Group has a presence in 22 countries and a turnover of $690M (2017). 3 100 collaborators participate in these missions, among which 9 industrial sites serve the needs of our clients. URGO developed a sound portfolio of very well-known brands such as Mercurochrome, Alvityl, Juvamine, Sonalto, Ricqlès, Urgo, all serving the Group’s global ambition.
To prepare the future, UrgoTech, the group’s internal start-up has the mission to explore and offer patients the benefits of connected healthcare through artificial intelligence, digital and neurotechnologies which can bring life-changing therapies.
For more information, please visit http://www.urgo-group.com
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.